



G Medical Innovations Holdings Ltd  
ARBN 617 204 743

28 August 2018

Sandra Wutete  
Senior Adviser, Listings Compliance

By email:  
sandra.wutete@asx.com.au  
tradinghaltsperth@asx.com.au

Dear Ms Wutete

We refer to your letter dated 28 August 2018 noting the change in the price of GMV's securities from a low of \$0.275 on Tuesday 21 August 2018 to an intraday high of \$0.41 at the time of writing today, Tuesday 28 August 2018.

As requested, please find G Medical's response to each of the following questions and requests for information:

1. **Is GMV aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?**

No. G Medical is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.

2. **If the answer to question 1 is "yes":**

- a) **Is GMV relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?**

**Please note that the recent trading in GMV's securities would suggest to ASX that such information may have ceased to be confidential and therefore GMV may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.**

Not applicable.

- b) **Can an announcement be made immediately?**

**Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).**

Not applicable.

- c) **If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?**

Not applicable.

**3. If the answer to question 1 is “no”, is there any other explanation that GMV may have for the recent trading in its securities?**

G Medical recently made an announcement to the market on 8 August 2018 with regards to its plan to list its Chinese subsidiary, Guangzhou Yimei Innovative Medical Science and Technology Co. Ltd (“GYIMSTC Ltd”), on the main board of The Stock Exchange of Hong Kong Limited. Under the proposed listing, “GYIMSTC Ltd” would spin off from G Medical Innovations Holdings Limited, with G Medical retaining not less than a 50% ownership stake in the newly-listed GYIMSTC Ltd.

The management of G Medical Innovations have appointed global Investment Bank, UOB Kay Hian (Hong Kong) Limited to act as the financial adviser to the proposed IPO, with all parties working towards a listing within the next 6 to 9 months.

Under the terms of the agreement with UOB, UOB will obtain an in-principle approval from the Hong Kong Stock Exchange to proceed with the listing application, with the initial market capitalisation of GYIMSTC Ltd to be at least HK\$1,500,000,000.

Funds raised from this listing will provide substantial working capital and fuel the research and development of innovative mobile health solutions and enable continued investment into state-of-the-art manufacturing facilities. The amount of capital to be raised will be determined closer to the proposed IPO.

G Medical Innovations cautions investors that there can be no certainty that the proposed IPO will be proceed, and that the listing is subject to satisfaction of all legal and regulatory requirements. Shareholders will be updated throughout the process as appropriate.

G Medical understands that the proposed IPO of GYIMSTC Ltd may explain the recent trading in its securities.

**4. Please confirm that GMV is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.**

We confirm that GMV is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

**5. Please confirm that GMV’s responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of GMV with delegated authority from the board to respond to ASX on disclosure matters.**

We confirm that GMV’s responses to the questions have been authorised and approved by an officer of GMV with delegated authority from the Board to respond to ASX on disclosure matters.

Yours sincerely

Steven Wood

**Company Secretary**  
**G Medical Innovations Holdings Ltd**



28 August 2018

**Mr Steven Wood**

Company Secretary  
G Medical Innovations Holdings Limited

*By email*

Dear Mr Wood

**G Medical Innovations Holdings Limited (the “Entity”): price query**

We note the change in the price of the Entity’s securities from a closing price of \$0.275 on Tuesday, 21 August 2018 to an intra-day high at the time of writing of \$0.41 today, Tuesday 28 August 2018.

In light of this, ASX asks the Entity to respond separately to each of the following questions and requests for information:

1. Is the Entity aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is “yes”:
  - a) Is the Entity relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?

Please note that the recent trading in the Entity’s securities would suggest to ASX that such information may have ceased to be confidential and therefore the Entity may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is “yes”, you need to contact us immediately to discuss the situation.
  - b) Can an announcement be made immediately?

Please note, if the answer to this question is “no”, you need to contact us immediately to discuss requesting a trading halt (see below).
  - c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is “no”, is there any other explanation that the Entity may have for the recent trading in its securities?
4. Please confirm that the Entity is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that the Entity’s responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of the Entity with delegated authority from the board to respond to ASX on disclosure matters.

**When and where to send your response**

This request is made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by not later than **3:00 pm (WST) today, Tuesday 28 August 2018**. If we do not have your response by then, ASX will have no choice but to consider suspending trading in the Entity’s securities under Listing Rule 17.3.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, the Entity’s obligation is to disclose the information “immediately”. This may require the information to be disclosed before the deadline set out in the previous paragraph.

---

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me copying in [TradingHaltsPerth@asx.com.au](mailto:TradingHaltsPerth@asx.com.au). It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### **Listing Rules 3.1 and 3.1A**

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

In responding to this letter, you should have regard to the Entity's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*.

It should be noted that the Entity's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### **Trading halt**

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in the Entity's securities under Listing Rule 17.1.

If you wish to request a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

If you have any queries or concerns about any of the above, please contact me immediately.

Kind regards

*[Sent electronically without signature]*

---

**Sandra Wutete**  
Senior Adviser, Listings Compliance (Perth)